Introduction Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease for which
two effective antifibrotics, nintedanib and pirfenidone, are available. However, many patients …

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease lacking
effective therapeutics. Treatment with pirfenidone or nintedanib is recommended for patients …

Background Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are
scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for …

Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …

Rationale: Since their approval, there has been no real-world or randomized trial evidence
evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically …

Abstract Background Research questions To compare the efficacy of nintedanib and
pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of …

Background Two antifibrotic drugs, pirfenidone and nintedanib, are licensed for the
treatment of patients with idiopathic pulmonary fibrosis (IPF). However, there is neither …

Background The antifibrotic drugs nintedanib and pirfenidone reduce disease progression
in idiopathic pulmonary fibrosis (IPF) and have also shown to improve survival. Switching …

Background Real-life data on the use of pirfenidone and nintedanib to treat patients with
idiopathic pulmonary fibrosis (IPF) are still scarce. Methods We compared the efficacy of …

Methods: In this randomized, open-label, selection design phase II trial, patients with IPF
and a≥ 5% relative decline in FVC within 6 months of the pirfenidone administration period …